Atherosclerosis: Diet and Drugs (eBook)

Arnold Eckardstein (Herausgeber)

eBook Download: PDF
2005 | 2005
XII, 816 Seiten
Springer Berlin (Verlag)
978-3-540-27661-6 (ISBN)

Lese- und Medienproben

Atherosclerosis: Diet and Drugs -
Systemvoraussetzungen
523,23 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
Cardiovascular diseases continue to be the leading cause of death in the - jority of industrialized countries. The most frequent underlying pathology, namely atherosclerosis, and its clinical sequelae, namely coronary heart d- ease, cerebrovascular disease and peripheral artery disease, remain common although for a long time we have been made aware of avoidable or mo- ?able etiological factors such as smoking, fat-rich diet or lack of exercise, and although these adverse lifestyle factors have been extensively addressed by population-wide primary prevention programs. Cardiovascular morbidity and mortality also remain high despite successful anti-hypertensive and lipid lowering drug therapies which help to reduce cardiovascular morbidity and mortality by about 30% in both secondary and tertiary prevention settings. This can partly be explained by the increasing life expectancy and growing p- portionofelderly people,especiallyinEuropeandNorthAmerica. Inaddition, the World Health Organization makes the alarming prediction that probably in response to the spreading of western dietary behavior and lack of exercise resulting in an increasing prevalence of diabetes, dyslipidemia and hypert- sion, cardiovascular diseases rather than infectious diseases will become the most frequent cause of death worldwide. This volume of the Handbook of Experimental Pharmacology entitled 'Atherosclerosis' is divided into four parts and intends to give an overview on the pathogenesis of atherosclerosis, established treatment and prevention regimen, and of perspectives for the development of new treatment modalities.

Preface 5
List of Contents 7
List of Contributors 10
Background 12
The Pathogenesis of Atherosclerosis 13
Risk Factors for Atherosclerotic Vascular Disease 81
Metabolic Syndrome: Therapeutic Considerations 116
The Impact of Diet 143
Physical Activity, Obesity and Cardiovascular Diseases 144
Fatty Acids and Atherosclerotic Risk 171
Dietary Cholesterol, Atherosclerosis and Coronary Heart Disease 201
Plant Sterols and Stanols 220
Carbohydrates and Dietary Fiber 236
Dietary Antioxidants and Paraoxonases Against LDL Oxidation and Atherosclerosis Development 267
Soy, Isoflavones and Atherosclerosis 305
Homocysteine and B Vitamins 328
Alcohol 342
Evidence-Based Anti-Atherosclerotic Drug Therapy 365
Lipid and Non-lipid Effects of Statins 366
Fibrates 390
ACE Inhibitors and Angiotensin II Receptor Antagonists 408
Inhibition of Platelet Activation and Aggregation 444
Targets of Future Anti-Atherosclerotic Drug Therapy 464
The ABC of Hepatic and Intestinal Cholesterol Transport 465
Inhibition of the Synthesis of Apolipoprotein B-Containing Lipoproteins 483
Therapy of Hyper-Lp(a) 518
Modulation of High-Density Lipoprotein Cholesterol Metabolism and Reverse Cholesterol Transport 536
Inhibition of Lipoprotein Lipid Oxidation 561
Correction of Insulin Resistance and the Metabolic Syndrome 589
Protection of Endothelial Function 616
Modulation of Smooth Muscle Cell Proliferation and Migration: Role of Smooth Muscle Cell Heterogeneity 642
Modulation of Macrophage Function and Metabolism 661
Inflammation Is a Crucial Feature of Atherosclerosis and a Potential Target to Reduce Cardiovascular Events 692
Autoimmune Mechanisms of Atherosclerosis 718
Drug Therapies to Prevent Coronary Plaque Rupture and Erosion: Present and Future 739
Reciprocal Role of Vasculogenic Factors and Progenitor Cells in Atherogenesis 771
Gene Therapy of Atherosclerosis 778
Subject Index 801

Erscheint lt. Verlag 2.11.2005
Reihe/Serie Handbook of Experimental Pharmacology
Handbook of Experimental Pharmacology
Zusatzinfo XII, 816 p.
Verlagsort Berlin
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Innere Medizin
Medizin / Pharmazie Pharmazie
Schlagworte Angiotensin II • atherosclerosis • Cardiovascular • gene therapy • Heart disease • Metabolic disease • prevention • risk factors • Vascular Biology
ISBN-10 3-540-27661-0 / 3540276610
ISBN-13 978-3-540-27661-6 / 9783540276616
Haben Sie eine Frage zum Produkt?
PDFPDF (Ohne DRM)

Digital Rights Management: ohne DRM
Dieses eBook enthält kein DRM oder Kopier­schutz. Eine Weiter­gabe an Dritte ist jedoch rechtlich nicht zulässig, weil Sie beim Kauf nur die Rechte an der persön­lichen Nutzung erwerben.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich